Treatment of elderly patients with intermediate- and high-grade non-Hodgkin's lymphoma: a retrospective population-based study

Purpose and methods: Nowadays more people are becoming older. The median ag e of a patient with non-Hodgkin's lymphoma (NHL) at diagnosis is over 60 ye ars. The incidence of NHL in elderly has increased in the last decades. The refore, in the future, NHL will be diagnosed more often in the elderly. Dat a of all patients in the south-east of the Netherlands with newly diagnosed NHL between January 1991 and January 1995 were analysed in a retrospective multicentre population-based study to investigate if and how elderly patie nts (> 60 years) with advanced NHL (Ann Arbor Staging greater than or equal to IIB) of intermediate- and high-grade malignancy were treated. Treatment modalities applied, outcome, and causes of death were evaluated. Treatment was considered inadequate if it deviated from the standard anthracycline-c ontaining chemotherapy (CNOP/CHOP) fora minimum of six cycles. Results: The entry criteria were met by 68 patients. Of these patients, 57 (83.8%) were treated and 11 (16.2%) were not treated. The treatment consisted of CHOP ( 36 patients), CNOP (6 patients), chlorambucil(13 patients), or COP (2 patie nts). Forty two of 68 patients had adequate treatment, but 14 of 42 (33.3%) patients had a suboptimal numbers of cycles (<6). Of 28 patients with adeq uate chemotherapy, only 16 had the optimal number of cycles and dose; the r esult is that the treatment of 76.5% (52/68) of patients differed from that of their younger counterparts. The most important reason for treatment not being optimal was high age (23%) or poor performance (35%). In the appropr iately treated patients, 62.5% (10/16) had a complete response. Survival in the CHOP/CNOP-treated group was better than in other groups. The main caus e of death in the total study group was NHL. The results cannot be explaine d by the different international prognostic index. Conclusion. A significan t subset (76.5%) of elderly people with intermediate/high-grade NHL receive d suboptimal therapy, mainly because of a suboptimal performance status. Ho wever, a significant part of the patients (23%) were not treated optimally because of high age, despite a good performance. For improving the overall survival in the elderly, it is not only the schedule that is important, but also the intention to treat the elderly patient.